LGND News & Analysis
2 articles
Market Mood
Ligand Pharma (LGND) Exec Sells $1.52 Million in Stock
Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals (LGND), sold company stock valued at $1.52 million. The transaction involved the sale of 14,950 shares at an average price of $101.61 each. This sale follows other insider transactions within the company over recent months. Insider sales can sometimes indicate an executive's view on the stock's current valuation or future prospects. This matters to investors as such transactions might influence perceptions regarding the company's future performance and stock value.
Read More: Ligand Pharma (LGND) Exec Sells $1.52 Million in Stock
Ligand Pharma (LGND) Stock Target Raised After XOMA Acquisition
Bank of America (BofA) has raised its price target for Ligand Pharmaceuticals (LGND) following the company's acquisition of XOMA Corporation. This move reflects confidence in the combined entity's potential to enhance market presence. No specific new price target was provided in the announcement. The acquisition is expected to have a positive impact on Ligand's growth trajectory, which may influence investor sentiment and market performance moving forward.
Read More: Ligand Pharma (LGND) Stock Target Raised After XOMA Acquisition